🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Reliability of IUS in Crohn's Disease

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire, Amiens
NCT06833450 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD). In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic targets to ensure comparability between future studies, the inter-observer agreement should be determined for all relevant parameters.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Crohn's disease evolving for at least 1 months * Patient older than 18 years * Patient covered by French national health insurance * Written informed consent Exclusion Criteria: * Pregnant women or breastfeeding * Minor * Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
💊

What it tests

  • Transabdominal intestinal ultrasound
📍

Where

1 site
CHU d'Amiens
Amiens, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy